• Vertigenius

  Participated · Equity · Apr 2026

  Vertigenius develops a wearable head-sensor medical device and platform that enables clinicians to remotely monitor vertigo patients and track treatment progress. The company registered with the FDA and launched in the US in October, where 20 clinics in 11 states have used its device to treat around 3,000 patients. Vertigenius says its platform accelerates clinician workflows, reduces clinic visits, and enables clinics to access additional insurance reimbursement for remote monitoring in the US. The company positions the US as an addressable market of over €3bn with more than 5,000 vestibular clinics and plans to grow its US commercial presence. With a €2.55m raise following a €2.1m round in 2024, Vertigenius will hire across clinical research, product R&D, quality assurance and regulatory affairs while maintaining its Irish headquarters. Vertigenius aims to expand further across Europe and into Asia Pacific over the next five years.

• CroíValve

  Participated · Series B · Aug 2024

  CroíValve is developing the DUO System, a novel transcatheter heart valve that preserves native anatomy and works in tandem with the tricuspid valve to restore function while avoiding contact with critical right-heart structures. The DUO Adapt System features an adaptive coaptation valve designed to fill larger and complex leaks and has shown early clinical use treating leaks up to 35mm with significant reduction in tricuspid regurgitation. The device is investigational and not for sale in any geography. CroíValve plans to expand its TANDEM II prospective, multicenter study across additional US and EU sites to further evaluate safety and performance, building on 15 patients already treated. The company recently expanded its Series B financing and secured grant funding to support this clinical expansion, and has R&D and operations in Ireland with clinical and regulatory functions in the US.

• Bluedrop Medical

  Participated · Equity · Mar 2023

  Bluedrop Medical is a medical technology company headquartered in Galway. The article presents the firm broadly within the medtech sector but does not specify its core product or service. In its latest development, the company secured a €1 million investment from Enterprise Ireland, signalling continued institutional confidence. This funding suggests the business is still in an expansionary, early-stage phase focused on advancing its technology and market presence. No revenue figures, user numbers, or other operating metrics were disclosed, and the piece offers no details on any earlier funding activity.

No current team members are available.